The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.